Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 7,763 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Terminated Phase 4 Interventional Results available

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

NCT00374543
View directory record Official record
Conditions
Generalized Anxiety Disorder, Bipolar Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 9, 2026, 2:52 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

NCT04590508
View directory record Official record
Conditions
Crohn Disease
Interventions
Xanthohumol, Placebo
Drug · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Early Phase 1 Interventional Results available

COGNUTRIN in Breast Cancer Survivors

NCT01823991
View directory record Official record
Conditions
Breast Cancer
Interventions
VitaBlue™, Placebo, Lovaza®
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients

NCT00679991
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
PRT-201
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Portland, Maine + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 9, 2026, 2:52 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

NCT05037929
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Astegolimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 90 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Dothan, Alabama • Jasper, Alabama • Mobile, Alabama + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cocoa and Endothelial Function in Adults With Elevated BMI

NCT00538083
View directory record Official record
Conditions
Cardioprotection
Interventions
Chocolate
Other
Lead sponsor
Griffin Hospital
Other
Eligibility
30 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

NCT02185794
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

NCT02576639
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CNP520, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Glendale, California • Long Beach, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

NCT05119920
View directory record Official record
Conditions
Dry Eye Disease, Kerato Conjunctivitis Sicca
Interventions
Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
19
States / cities
Chandler, Arizona • Sun City, Arizona • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Transcranial Photobiomodulation in Autism Spectrum Disorder

NCT05363982
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Transcranial Photobiomodulation (tPBM), Placebo/ Sham
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 59 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

NCT03950882
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
PXL770, Placebo
Drug
Lead sponsor
Poxel SA
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

NCT04882124
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Andalusia, Alabama • Crowley, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 9, 2026, 2:52 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

NCT02563522
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
Engensis (VM202), Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 9, 2026, 2:52 PM EDT
Recruiting Not applicable Interventional

Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

NCT05102929
View directory record Official record
Conditions
Schizophrenia
Interventions
active intermittent Theta Burst Stimulation (iTBS), sham intermittent Theta Burst Stimulation (iTBS)
Device
Lead sponsor
Fabio Ferrarelli
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition Interventions for Cognitive Enhancement

NCT03841539
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Mediterranean Diet, Study Supplement, Low-fat Diet
Behavioral · Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

NCT00456586
View directory record Official record
Conditions
Parkinson's Disease
Interventions
KW-6002 (istradefylline)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

NCT00300469
View directory record Official record
Conditions
Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia
Interventions
ABT-335, Atorvastatin, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 9, 2026, 2:52 PM EDT
Active, not recruiting Phase 3 Interventional

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

NCT06615557
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
Fasedienol Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy

NCT04590066
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu shot text messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
734,383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 9, 2026, 2:52 PM EDT
Not yet recruiting Phase 2 Interventional

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

NCT06710431
View directory record Official record
Conditions
Alcohol Abuse, Alcohol Abuse/addiction, Anxiety, Pain Threshold, Depression Disorders, Sleep Disorder
Interventions
AFA-281
Drug
Lead sponsor
Afasci Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

NCT00893841
View directory record Official record
Conditions
Bipolar Depression
Interventions
quetiapine (Seroquel) XR, placebo, pramipexole dihydrochloride
Drug
Lead sponsor
Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
San Diego, California • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 9, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

NCT03081156
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler
Drug
Lead sponsor
William Stringer, md
Other
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 9, 2026, 2:52 PM EDT
Terminated Not applicable Interventional Results available

Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease

NCT00638222
View directory record Official record
Conditions
Vascular Disease, Kidney Disease
Interventions
Carvedilol and Placebo
Other
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Toledo, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 9, 2026, 2:52 PM EDT